These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 31352980)

  • 21. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
    Paterno G; Del Principe MI; Venditti A
    Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
    Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease in acute myeloid leukemia: coming of age.
    Paietta E
    Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
    Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
    Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.
    Chen X; Cherian S
    Clin Lab Med; 2021 Sep; 41(3):467-483. PubMed ID: 34304776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
    Roug AS; Ommen HB
    Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease quantitation in acute myeloid leukemia.
    Shook D; Coustan-Smith E; Ribeiro RC; Rubnitz JE; Campana D
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S281-5. PubMed ID: 19778853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
    Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
    Yu T; Chi J; Wang L
    Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
    Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
    Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.